Gut 圓桌會議紀要：肝細胞癌最新進展

Alexander Gerbes,Fabien Zoulim,Herbert Tilg,Jean- Fran?ois Dufour,Jordi Bruix, ValérieParadis, Riad Salem,Markus Peck-Radosavljevic, Peter R Galle, Tim F Greten, Jean-Charles Nault, Matias A Avila

本期負責人：茅益民上海交通大學醫學院附屬仁濟醫院消化內科

審校：唐潔婷 茅益民 上海交通大學醫學院附屬仁濟醫院消化內科

翻譯：雷曉紅上海交通大學醫學院附屬仁濟醫院消化內科

摘要

全球範圍內， 肝細胞癌（hepatocellular carcinoma，HCC）的死亡率在所有實體性腫瘤中高居第三位。隨著肥胖和脂肪肝這些危險因素的不斷增加，HCC 日益成為臨床面臨的巨大挑戰。目前，對於多數患者仍沒有治癒性治療措施，很多新葯進入臨床試驗，然而大多數在III 期臨床試驗中最終失敗。本文針對HCC 治療最新進展和相關熱點問題，總結了專家要點摘要並提出了急需研究的問題，如包括微生物群在內的危險因素、預後及預測的生物標誌物以及尚存爭議的肝活檢的作用等。重點討論的治療策略包括局部治療、聯合治療和免疫治療的可能性。最後，本文評價了HCC 個體化治療的新靶點和策略。

Gut roundtable meeting paper: selected recent advances inhepatocellular carcinoma

Alexander Gerbes,Fabien Zoulim,Herbert Tilg,Jean- Fran?ois Dufour,Jordi Bruix, ValérieParadis, Riad Salem,Markus Peck-Radosavljevic, Peter R Galle, Tim F Greten, Jean-Charles Nault, Matias A Avila

ABSTRACT

Hepatocellular carcinoma (HCC) ranks number three among the most frequent causes of death from solid tumors worldwide. With obesity and fatty liver diseases as risk factors on the rise, HCC represents an ever increasing challenge. While there is still no curative treatment for most patients numerous novel drugs have been proposed, but most ultimately failed in phase III trials. This manuscript targets therapeutic advances and most burning issues. Expert key point summaries and urgent research agenda are provided regarding risk factors, including microbiota, need for prognostic and predictive biomarkers and the equivocal role of liver biopsy. Therapeutic topics highlighted are locoregional techniques, combination therapies and the potential of immunotherapy. Finally the manuscript provides a critical evaluation of novel targets and strategies for personalized treatment of HCC.

Gut Feb 2018, 67 (2) 380-388; DOI: 10.1136/gutjnl-2017-315068

https://gut.bmj.com/content/67/2/380

文章原文選自GUT原刊，歡迎個人轉發分享，任何媒體、網站如需轉載或引用，必須獲得授權且在醒目位置註明出處。

喜歡這篇文章嗎？立刻分享出去讓更多人知道吧！